Welcome to drugdiscoveryanddevelopment.co.uk
Click to listen highlighted text!
Welcome to drugdiscoveryanddevelopment.co.uk
Subscribe to newsletter
Facebook
Linkedin
X
Youtube
Linkedin
Twitter
Youtube
Tue 22 September 2026
A Pharma Press Global company
Subscribe to DDD newsletter
Search
Drug Discovery and Development
Drug Discovery
Investigational New Drug application
Phase 1-2 trials
Phase 3 trials
Approvals
Finance
Conferences
Journal
Drug Discovery
Investigational New Drug application
Phase 1-2 trials
Phase 3 trials
Approvals
Novartis remibrutinib significantly reduces relapse rates and shows favourable safety profile in phase 3 RMS trials
9 September 2026
GSK to advance mRNA seasonal flu vaccine candidate to phase 3 following positive phase 2 data
9 September 2026
New phase 3b data on Eli Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults...
8 September 2026
Acoramidis demonstrates reversal of cardiac structural disease progression and functional decline and significantly increases days alive and free from hospitalisation in ATTR-CM
8 September 2026
Tezspire demonstrates positive phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
8 September 2026
Products
CDMO
CRO
Home
Authors
Posts by Julian English
Julian English
36 POSTS
0 COMMENTS
https://drugdiscoveryanddevelopment.co.uk
Phase 1-2 trials
Amgen advances toward lupus redemption while gastric cancer candidate struggles
Julian English
-
6 February 2026
0
Phase 3 trials
Phase 3 antifungal trial cancelled over low response, higher mortality rate
Julian English
-
5 February 2026
0
Phase 3 trials
Hutchmed to file for approval of sovleplenib in China in the first half of 2026
Julian English
-
5 February 2026
0
Basilea to collaborate with US biotech to develop new antifungal drug
Julian English
-
5 February 2026
0
Approvals
Nanoform outlicenses Nanoencorafenib and signs development and commercialisation agreement with A.forall and IMGA
Julian English
-
1 February 2026
0
Kazia Therapeutics announces compelling preclinical and translational data for nuclear PD-L1 degrader (NDL2)
Julian English
-
31 January 2026
0
1
2
3
4
Page 4 of 4
TOP AUTHORS
Editor
162 POSTS
0 COMMENTS
https://drugdiscoveryanddevelopment.co.uk
Julian English
36 POSTS
0 COMMENTS
https://drugdiscoveryanddevelopment.co.uk
Most Read
Novartis remibrutinib significantly reduces relapse rates and shows favourable safety profile in phase 3 RMS trials
9 September 2026
GSK to advance mRNA seasonal flu vaccine candidate to phase 3 following positive phase 2 data
9 September 2026
New phase 3b data on Eli Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults...
8 September 2026
Acoramidis demonstrates reversal of cardiac structural disease progression and functional decline and significantly increases days alive and free from hospitalisation in ATTR-CM
8 September 2026
Click to listen highlighted text!